Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 2Plasma cell 1Other hematologic neoplasm 1Lymphoid 1Genitourinary 1CNS 1

Conditions

Neoplasms, Plasma Cell 1Neoplasms, Germ Cell and Embryonal 1Multiple Myeloma 1Lymphoma 1Leukemia 1

Interventions

Cytarabine 184Cyclophosphamide 176fludarabine 146Azacitidine 121venetoclax 115fludarabine phosphate 104Rituximab 80Decitabine 74Filgrastim 58Specimen Handling 55Etoposide 55Lenalidomide 47Biopsy 45Dexamethasone 41Methotrexate 40Bortezomib 40Mitoxantrone 39Granulocyte Colony-Stimulating Factor 39Daunorubicin 39Vincristine 37Melphalan 36ibrutinib 35Tacrolimus 35Dasatinib 34Whole-Body Irradiation 32Clofarabine 32Peripheral Blood Stem Cell Transplantation 31Mycophenolic Acid 31Injections 31Idarubicin 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × keyhole-limpet hemocyanin × Other hematologic neoplasm × Clear all
NCT00369291 2017-11-29

CpG 7909 in Treating Patients Who Have Undergone Autologous Stem Cell Transplant

Masonic Cancer Center, University of Minnesota

Phase 1 Terminated
19 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Leukemia, Lymphoma, Multiple Myeloma, Neoplasms, Germ Cell and Embryonal, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡